The biopharmaceutical company said it has entered into an agreement with Parexel, a clinical research organization, to conduct the study of PRV-031.
The Oldwick, New Jersey, company said recent milestones include the announcement with Amgen Inc (NASDAQ:AMGN) of a licensing and co-development agreement for PRV-015, a monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease.
READ: Kodiak Sciences pushes ahead with trials for diabetic eye disease drug as it unveils 3Q results
“Over the course of 2019, we expect a steady cadence of data readouts from ongoing studies designed to illustrate the potential of our approach,” CEO Ashleigh Palmer said in a statement.
For the fourth quarter, the company reported a